<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340082</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Using Vaccine Safety Data to Demonstrate the Potential of Pooled Data Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091052</ELocationID><Abstract><AbstractText>In Canada, vaccine safety studies are often conducted at the provincial/territorial level where the primary data on vaccination reside. Combining health services data from multiple jurisdictions using a pooled data analytic approach would reduce the amount of time needed to detect vaccine safety signals. To determine the difference in the time it would take to identify safety signals using different proportions of the Canadian population, we conducted power and sample size calculations for a hypothetical self-controlled case series-based surveillance analysis. We used scenarios modeled after the real-world examples of myocarditis and vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination as our base cases. Our calculations demonstrated that in the case of a myocarditis-type event, a pooled analysis would reduce the time needed to detect a safety signal by over 60% compared to using Ontario data alone. In the case of a VITT-type event, a pooled analysis could detect a safety signal 49 days sooner than using Ontario data alone, potentially averting as many as 30 events. Our analysis demonstrates that there is substantial value in using pan-Canadian health services data to evaluate the safety of vaccines. Efforts should be made to develop a pan-Canadian vaccine data source to allow for an earlier evaluation of suspected adverse events following immunization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hawken</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1053 Carling Avenue, Ottawa, ON K1Y 4E9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Cres., Ottawa, ON K1G 5Z3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Kumanan</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1741-7705</Identifier><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1053 Carling Avenue, Ottawa, ON K1Y 4E9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bruyere Research Institute, Ottawa, ON K1R 6M1, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CANImmunize Inc., Ottawa, ON K2A 2E5, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NA</GrantID><Agency>Public Health Agency of Canada</Agency><Country /></Grant><Grant><GrantID>NA</GrantID><Agency>Canadian Institutes for Health Research</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">adverse events following immunization</Keyword><Keyword MajorTopicYN="N">pooled data</Keyword><Keyword MajorTopicYN="N">self-controlled case series</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword></KeywordList><CoiStatement>K.W. was a past member of Medicago’s Independent Data Monitoring Committee, Moderna’s Global Safety Advisory Core Consultancy Group. He is Co-founder and Chief Scientific Officer of CANImmunize Inc. L.A.W. has consulted for CANImmunize Inc within the past three years. SH has consulted for CANImmunize Inc within the past three years.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340082</ArticleId><ArticleId IdType="pmc">PMC11436156</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091052</ArticleId><ArticleId IdType="pii">vaccines12091052</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Government of Canada  Canadian Immunization Registry Functional Standards 2020 to 2024: Recommendations from the Canadian Immunization Registry and Coverage Network.  [(accessed on 22 January 2024)];2023  Available online:  https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-registry-functional-standards-2020-2024.html.</Citation></Reference><Reference><Citation>Government of Canada SC  Profile Table, Census Profile, 2021 Census of Population—Canada.  [(accessed on 22 January 2024)];2022  Available online:  https://www12.statcan.gc.ca/census-recensement/2021/dp-pd/prof/index.cfm?Lang=E.</Citation></Reference><Reference><Citation>Government of Canada  Highlights from the 2021 Childhood National Immunization Coverage Survey (cNICS)  [(accessed on 22 January 2024)];2023  Available online:  https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/2021-highlights-childhood-national-immunization-coverage-survey.html.</Citation></Reference><Reference><Citation>Government of Canada  Vaccine Uptake in Canadian Adults 2021.  [(accessed on 22 January 2024)];2022  Available online:  https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/highlights-2020-2021-seasonal-influenza-survey/full-report.html.</Citation></Reference><Reference><Citation>Government of Canada  Seasonal Influenza Vaccination Coverage in Canada, 2021–2022: Full Report.  [(accessed on 22 January 2024)];2022  Available online:  https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/seasonal-influenza-survey-results-2021-2022/full-report.html.</Citation></Reference><Reference><Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario)  Myocarditis and Pericarditis after COVID-19 mRNA Vaccines. Queen’s Printer for Ontario.  [(accessed on 22 January 2024)];2022  Available online:  https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/11/myocarditis-pericarditis-mrna-vaccines.pdf?sc_lang=en.</Citation></Reference><Reference><Citation>Husby A., Gulseth H.L., Hovi P., Hansen J.V., Pihlström N., Gunnes N., Härkänen T., Dahl J., Karlstad Ø., Heliö T., et al. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: Population based cohort study. BMJ Med. 2023;2:e000373. doi: 10.1136/bmjmed-2022-000373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000373</ArticleId><ArticleId IdType="pmc">PMC9978676</ArticleId><ArticleId IdType="pubmed">36936260</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrington P., Whitaker H., Weldeselassie Y.G. Self-Controlled Case Series Studies: A Modelling Guide with R. 2nd ed. Chapman and Hall/CRC; Boca Raton, FL, USA: 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/9780429491313</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker H.J., Paddy Farrington C., Spiessens B., Musonda P. Tutorial in biostatistics: The self-controlled case series method. Stat. Med. 2006;25:1768–1797. doi: 10.1002/sim.2302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2302</ArticleId><ArticleId IdType="pubmed">16220518</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai M., Chan B., Stall N.M., Grill A., Ivers N., Maltsev A., Miller K.J., Odutayo A., Razak F., Schull M., et al. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination. Ontario COVID-19 Science Advisory Table. . Sci. Briefs Ont. COVID-19 Sci. Advis. Table . 2021;2:1–7. doi: 10.47326/ocsat.2021.02.17.2.0.</Citation><ArticleIdList><ArticleId IdType="doi">10.47326/ocsat.2021.02.17.2.0</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins H., Andrews N., Stowe J., Amirthalingam G., Ramsay M., Bahra G., Hackett A., Breen K.A., Desborough M., Khan D., et al. Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England. Res. Pract. Thromb. Haemost. 2022;6:e12698. doi: 10.1002/rth2.12698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12698</ArticleId><ArticleId IdType="pmc">PMC9020167</ArticleId><ArticleId IdType="pubmed">35475292</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldeselassie Y., Whitaker H., Farrington P. SCCS: The Self-Controlled Case-Series Method.  [(accessed on 22 January 2024)].  Available online:  https://CRAN.R-project.org/package=SCCS.</Citation></Reference><Reference><Citation>Hawken S. Time to Detect a Safety Signal in an SCCS Surveillance Analysis. 2023.  [(accessed on 22 January 2024)].  Available online:  https://stevenhawken.shinyapps.io/sccs_time_to_detect/</Citation></Reference><Reference><Citation>Xavier-Carter B. Ontario Tops 50,000 Vaccine Doses Administered on One Day for First Time. Toronto Star. 2021.  [(accessed on 22 January 2024)].  Available online:  https://www.thestar.com/news/gta/ontario-tops-50-000-vaccine-doses-administered-on-one-day-for-first-time/article_ac657ec9-a366-5bc4-b213-4ffe2daa9b48.html.</Citation></Reference><Reference><Citation>Pavord S., Scully M., Hunt B.J., Lester W., Bagot C., Craven B., Rampotas A., Ambler G., Makris M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N. Engl. J. Med. 2021;385:1680–1689. doi: 10.1056/NEJMoa2109908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109908</ArticleId><ArticleId IdType="pmc">PMC10662971</ArticleId><ArticleId IdType="pubmed">34379914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritzell B. Detection of Adverse Events: What are the Current Sensitivity Limits during Clinical Development? . Vaccine. 2001;20:S47–S48. doi: 10.1016/S0264-410X(01)00291-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00291-2</ArticleId><ArticleId IdType="pubmed">11587811</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed Z., Li J., Spencer M., Wilton J., Naus M., García H.A.V., Otterstatter M., Janjua N.Z. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: A population-based cohort study. CMAJ. 2022;194:E1529–E1536. doi: 10.1503/cmaj.220676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.220676</ArticleId><ArticleId IdType="pmc">PMC9828950</ArticleId><ArticleId IdType="pubmed">36410749</ArticleId></ArticleIdList></Reference><Reference><Citation>News CBC  “Mild Risk” Prompts Ontario to Recommend Pfizer over Moderna for Those Aged 18–24 | CBC News. CBC. 2021.  [(accessed on 22 January 2024)].  Available online:  https://www.cbc.ca/news/canada/toronto/covid-19-ontario-september-29-moore-briefing-update-1.6193455.</Citation></Reference><Reference><Citation>Barker CIS, Snape MD Pandemic influenza A H1N1 vaccines and narcolepsy: Vaccine safety surveillance in action. Lancet Infect. Diseases. 2014;14:227–238. doi: 10.1016/S1473-3099(13)70238-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70238-X</ArticleId><ArticleId IdType="pubmed">24360892</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans D., Cauchemez S., Hayden F.G. “Prepandemic” Immunization for Novel Influenza Viruses, “Swine Flu” Vaccine, Guillain-Barré Syndrome, and the Detection of Rare Severe Adverse Events. J. Infect. Dis. 2009;200:321–328. doi: 10.1086/603560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/603560</ArticleId><ArticleId IdType="pmc">PMC2811391</ArticleId><ArticleId IdType="pubmed">19563262</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong J.C., Vasa P.P., Campitelli M.A., Hawken S., Wilson K., Rosella L.C., Stukel T.A., Crowcroft N.S., McGeer A.J., Zinman L., et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: A self-controlled study. Lancet Infect. Dis. 2013;13:769–776. doi: 10.1016/S1473-3099(13)70104-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70104-X</ArticleId><ArticleId IdType="pubmed">23810252</ArticleId></ArticleIdList></Reference><Reference><Citation>CNODES | About CNODES.  [(accessed on 22 January 2024)].  Available online:  https://www.cnodes.ca/about/</Citation></Reference><Reference><Citation>Home | Global Vaccine Data Network.  [(accessed on 22 January 2024)].  Available online:  https://www.globalvaccinedatanetwork.org/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>